NED Biosystems raises $2 million in Series B round for planned cancer drug trial

The company, which is developing a combination treatment for cancers called NED-170, plans to start a Phase II trial next year.

More From BioPortfolio on "NED Biosystems raises $2 million in Series B round for planned cancer drug trial"